

Printed as of 7/1/2025

# **Disclosures**

#### Personal Commercial (2)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
Self			
Bayer Healthcare Pharmaceuticals	Consultant Fees/Honoraria	Significant (>= \$5,000)	General Cardiology
Novo Nordisk Inc.	Consultant Fees/Honoraria	Significant (>= \$5,000)	Stable Ischemic Heart Disease

# Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

#### Personal Organizational or Other Non-Commercial (4)

Non-Commercial Enity Name	Relationship Category	Compensation Level	Topic Area(s)
Self			
Amgen † Amgen Inc.	Research/Research Grants ‡ VESALIUS	None (\$0)	General Cardiology
Boehringer Ingelheim † I receive no direct salary support for this study.	Research/Research Grants  ‡ EMPACT-MI	Significant (>= \$5,000)	Acute Coronary Syndromes
CSL Behring	Research/Research Grants ‡ AEGIS-II	None (\$0)	Acute Coronary Syndromes
Janssen	Research/Research Grants  ‡ LIBRIXIA-ACS	None (\$0)	Acute Coronary Syndromes

# Clinical Trial Enroller (4)

Trial Name	Trial Sponsor	Trial Funding Source
ACURATE	Boston Scientific	Boston Scientific
TRISCEND	Edwards	Edwards
CLASP-TR	Edwards	
ZEUS Trial	Novo Nordisk Inc.	

# Institutional Financial Decision-Making Role (0)

No disclosures on record

#### **Expert Witness Testimony (1)**

Year	Case Title	Represented	Description	Compensation
Self				
2022	Medical Necessity	Third Party † US Department of Justice		Significant (>= \$5,000)

† Commercial Funding Source | ‡ Trial Name

#### Agreement

Certified Education Attestation | Signed on 10/30/2024

URL for full agreement: http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement

Confidentiality, Disclosure and Assignment Agreement | Signed on 10/30/2024

URL for full agreement: http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement

**Embargo** | Signed on 10/30/2024

URL for full agreement: http://disclosures.acc.org/Public/Definition/EmbargoAgreement

#### On-Going Obligation Agreement | Signed on 10/30/2024

# **ACC** and **Disclosures**

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.